Alphamab Oncology Receives IND Application Acceptance for First-in-Class Dual Payload Bispecific ADC JSKN021

Key Highlights for Investors

• IND Application for JSKN021 Officially Accepted: Alphamab Oncology has announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has officially accepted its Investigational New Drug (IND) application for JSKN021.
• Innovative Drug Candidate: JSKN021 is an independently developed, first-in-class dual payload bispecific antibody-drug conjugate (ADC) targeting both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3).
• Planned Clinical Development: The company aims to initiate a Phase I clinical trial for JSKN021 in patients with advanced malignant solid tumors. The study will evaluate safety, tolerability, pharmacokinetics, anti-tumor activity, and determine the maximum tolerated dose and/or recommended Phase II dose.
• Preclinical Data Indicates Strong Efficacy: JSKN021 demonstrated significant efficacy in preclinical studies, inhibiting cancer cell growth with either HER3, EGFR, or both expressions. The compound also showed superior tumor inhibition compared to mono-payload ADCs in multiple cell-derived xenograft (CDX) models.
• Next-Generation ADC Technology: JSKN021 utilizes an EGFR/HER3 bispecific antibody conjugated with two novel payloads: a topoisomerase I inhibitor (T01, DAR 4) and Monomethyl auristatin E (MMAE, DAR 2). The design aims to address tumor heterogeneity and overcome resistance and non-response seen with single-payload ADCs, while minimizing toxicity.

Details of JSKN021

JSKN021 stands out as a first-in-class dual payload bispecific ADC, leveraging both EGFR and HER3 as targets. The bispecific antibody is chemically conjugated to two different cytotoxic payloads: topoisomerase I inhibitor (T01) and Monomethyl auristatin E (MMAE). This approach allows for:

• Enhanced anti-tumor efficacy by targeting tumor cells with variable expression of EGFR and HER3.
• Improved stability and homogeneity of the ADC, increasing the likelihood of sustained therapeutic benefit.
• Potential to overcome resistance mechanisms that limit the effectiveness of single-payload ADCs.
• Reduced on-target, off-tumor toxicity due to finely tuned binding avidity.

The preclinical results presented at the 2025 annual meeting of the American Association for Cancer Research highlighted JSKN021’s robust inhibition of tumor growth and its superiority over mono-payload ADCs in multiple preclinical models.

Company Overview and Strategic Positioning

Alphamab Oncology is a leading biopharmaceutical company in China, with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The company’s pipeline is highly differentiated, including one marketed product approved by the NMPA and several assets in late-stage clinical development for oncology.

The company’s expertise in proprietary protein engineering and structure-guided molecular modeling enables the creation of innovative biological drug candidates designed to address unmet medical needs globally.

Potential Price-Sensitive Information for Shareholders

• Regulatory Milestone Achieved: The IND acceptance for JSKN021 marks a significant regulatory and developmental milestone for Alphamab Oncology. This advancement could enhance market confidence and potentially impact the company’s share price.
• Pipeline Progression: Shareholders should note that the progression of JSKN021 into clinical trials strengthens the company’s position in the competitive ADC and oncology therapy market.
• Uncertainty Remains: As highlighted in the company’s cautionary statement, there is no guarantee that JSKN021 will successfully complete clinical development or achieve regulatory approval and commercialization. Investors should consider this risk when making investment decisions.

Board and Management

The board is chaired by Dr. Xu Ting, with Ms. Liu Yang serving as executive director, Mr. Cho Man as non-executive director, and Mr. Wu Dong, Ms. Wong Yan Ki Angel, and Dr. Gao Xiang as independent non-executive directors.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. While the acceptance of the IND application for JSKN021 represents a significant development for Alphamab Oncology, there is no assurance that the product will successfully complete clinical trials or be commercialized. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions.

View ALPHAMAB-B Historical chart here